A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
- Indications Early breast cancer; Male breast cancer
- Focus Adverse reactions
- 05 Nov 2019 Planned End Date changed from 1 Jun 2019 to 1 May 2020.
- 28 Jun 2019 Results published in the Annals of Oncology
- 30 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 May 2018.